Massimo Fresta

Prof. Massimo Fresta

Department of Health Sciences, University “Magna Græcia” of Catanzaro, Campus Universitario “S. Venuta”, viale Europa, 88100 Catanzaro, Italy
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2015 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
JWJoy Wolfram
Joy Wolfram
MZMotao Zhu
Motao Zhu
YYYong Yang
Yong Yang
JSJianliang Shen
Jianliang Shen
EGEmanuela Gentile
Emanuela Gentile
YZYuliang Zhao
Yuliang Zhao
Nanomedicine involves the use of nanoparticles for therapeutic and diagnostic purposes. During the past two decades, a growing number of nanomedicines have received regulatory approval and many more show promise for future clinical translation. In this context, it is important to evaluate the safety of nanoparticles in order to achieve biocompatibility and desired activity. However, it is unwarranted to make generalized statements regarding the safety of nanoparticles, since the field of nanomedicine comprises a multitude of different manufactured nanoparticles made from various materials. Indeed, several nanotherapeutics that are currently approved, such as Doxil and Abraxane, exhibit fewer side effects than their small molecule counterparts, while other nanoparticles (e.g. metallic and carbon-based particles) tend to display toxicity. However, the hazardous nature of certain nanomedicines could be exploited for the ablation of diseased tissue, if selective targeting can be achieved. This review discusses the mechanisms for molecular, cellular, organ, and immune system toxicity, which can be observed with a subset of nanoparticles. Strategies for improving the safety of nanoparticles by surface modification and pretreatment with immunomodulators are also discussed. Additionally, important considerations for nanoparticle safety assessment are reviewed. In regards to clinical application, stricter regulations for the approval of nanomedicines might not be required. Rather, safety evaluation assays should be adjusted to be more appropriate for engineered nanoparticles.

21 March 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Constantin MircioiuConstantin Mircioiu
Constantin Mircioiu
VVVictor A Voicu
Victor A Voicu
VAValentina Anuta
Valentina Anuta
ATAndra Tudose
Andra Tudose
Christian CeliaChristian Celia
Christian Celia
IMion mircioiu
ion mircioiu
Embedding of active substances in supramolecular systems has as the main goal to ensure the controlled release of the active ingredients. Whatever the final architecture or entrapment mechanism, modeling of release is challenging due to the moving boundary conditions and complex initial conditions. Despite huge diversity of formulations, diffusion phenomena are involved in practically all release processes. The approach in this paper starts, therefore, from mathematical methods for solving the diffusion equation in initial and boundary conditions, which are further connected with phenomenological conditions, simplified and idealized in order to lead to problems which can be analytically solved. Consequently, the release models are classified starting from the geometry of diffusion domain, initial conditions, and conditions on frontiers. Taking into account that practically all solutions of the models use the separation of variables method and integral transformation method, two specific applications of these methods are included. This paper suggests that “good modeling practice” of release kinetics consists essentially of identifying the most appropriate mathematical conditions corresponding to implied physicochemical phenomena. However, in most of the cases, models can be written but analytical solutions for these models cannot be obtained. Consequently, empiric models remain the first choice, and they receive an important place in the review.

1 December 1994 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
PWPeter Walde
Peter Walde
RWRoger Wick
Roger Wick
Massimo FrestaMassimo Fresta
Massimo Fresta
Annarosa MangoneAnnarosa Mangone
Annarosa Mangone
PLPier Luigi Luisi
Pier Luigi Luisi

12 September 2018 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EGElena Giuliano
Elena Giuliano
Donatella PaolinoDonatella Paolino
Donatella Paolino
Massimo FrestaMassimo Fresta
Massimo Fresta
Donato CoscoDonato Cosco
Donato Cosco
Poloxamer 407, also known by the trademark Pluronic® F127, is a water-soluble, non-ionic triblock copolymer that is made up of a hydrophobic residue of polyoxypropylene (POP) between the two hydrophilic units of polyoxyethylene (POE). Poloxamer 407-based hydrogels exhibit an interesting reversible thermal characteristic. That is, they are liquid at room temperature, but they assume a gel form when administered at body temperature, which makes them attractive candidates as pharmaceutical drug carriers. These systems have been widely investigated in the development of mucoadhesive formulations because they do not irritate the mucosal membranes. Based on these mucoadhesive properties, a simple administration into a specific compartment should maintain the required drug concentration in situ for a prolonged period of time, decreasing the necessary dosages and side effects. Their main limitations are their modest mechanical strength and, notwithstanding their bioadhesive properties, their tendency to succumb to rapid elimination in physiological media. Various technological approaches have been investigated in the attempt to modulate these properties. This review focuses on the application of poloxamer 407-based hydrogels for mucosal drug delivery with particular attention being paid to the latest published works.

1 August 2005 in Journal of Controlled Release
Verified
Journal Article
Closed access
Donatella PaolinoDonatella Paolino
Donatella Paolino
GLGiuseppe Lucania
Giuseppe Lucania
DMDomenico Mardente
Domenico Mardente
FAFranco Alhaique
Franco Alhaique
Massimo FrestaMassimo Fresta
Massimo Fresta

1 August 2009 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
Christian CeliaChristian Celia
Christian Celia
ETElena Trapasso
Elena Trapasso
Donato CoscoDonato Cosco
Donato Cosco
Donatella PaolinoDonatella Paolino
Donatella Paolino
Massimo FrestaMassimo Fresta
Massimo Fresta